



GOVERNMENT OF PAKISTAN  
(CABINET DIVISION)  
INTELLECTUAL PROPERTY ORGANIZATION  
THE PATENT OFFICE  
**KARACHI**



To,

Dated: 27/05/2011.

Umme Salma  
Assistant Director,  
IPO-Pakistan,  
**Islamabad.**

**Subject: WEEKLY NOTIFICATION OF PATENT AND INDUSTRIAL DESIGNS  
FOR THE WEEK-ENDING OF 21/05/2011 TO BE PUBLISHED . IN  
THE 30/05/2011 GAZETTE OF PAKISTAN PART-V.**

Sir,

Reference to IPO letter dated 12-5-2008 forwarding therewith copy of letter No. 18/IPO/2008/RA-IV dated 23-4-2008 from Cabinet Division on the above subject.

A manuscript copies of the weekly notification regarding application filed, application accepted and sealing fee due is enclosed herewith for onward transmission to the Cabinet Division for Publication in the next issue of the Gazette of Pakistan (Part –V)

**(Sabir Gul)**  
Controller of Patents  
& Registrar of Designs  
**Ph: 99215056**

**ENCL:**

## NEW APPLICATIONS FOR THE PATENTS

The dates shown in the crescent brackets are the dates claimed under section 86 of the Patents Ordinance 2000.

### **16-05-2011**

- |          |   |  |
|----------|---|--|
| 348/2011 | Renco Kompozit Teknolojileri<br>Sanayi VE Ticaret Limited Sirketi<br>Turkey<br>(Priority 21-04-2011 Turkey) | “A modular structure and said modular structure's structural members made of composite material”                                     |
| 349/2011 | Bossa Ticaret VE Sanayi<br>Isletmeleri Turk Anonim Sirketi<br>Turkey<br>(Priority 17-05-2010 Turkey)        | “Yarn produced by wrapping dyed/undyed fibres around a yarn dyed with indigo or another dyestuff and fabric produced with this yarn” |

### **17-05-2011**

- |          |   |   |
|----------|---|---|
| 350/2011 | Sanofi-Aventis<br>France<br>(Priority 19-05-2010 Europe)                                | “Long-acting formulations of insulin glargine”            |
| 351/2011 | Bayer Schering Pharma<br>Aktiengesellschaft<br>Germany<br>(Priority 26-05-2010 Germany) | “Substituted 5-fluoro-1H-pyrazolopyridines and their use” |
| 352/2011 | Eisai R&D Management Co., Ltd<br>Japan<br>(Priority 20-05-2010 USA)                     | “Prodrug of triazolone compound”                          |

### **18-05-2011**

- |          |   |                                   |
|----------|---|-----------------------------------|
| 353/2011 | Unilever PLC<br>United Kingdom<br>(Priority 31-05-2010 India)   | “A fortificant dispensing device” |
| 354/2011 | Brig. Raza-ul-mumen<br>Muhammad Akber<br>Ajaz Afzal<br>Nasir Javed<br>Sohaib Rahman<br>Patent Advirsory Cell<br>(DESTO)<br>HQ Chaklala, Rawalpindi<br>Paistan | “SECRET”                          |

355/2011	Dr.Zahid Kaleem Ghulam Abbas Patent Advirsory Cell DESTO HQ Chaklala, Rawalpindi Pakistan	“SECRET”
356/2011	Signal Point Partners Limited Mauritania (Priority 20-05-2010 Great Britain)	“Transaction processing and remote activation”
357/2011	Vestergaard Frandsen SA Switzerland (Priority 06-04-2011 Bangladesh)	“Biocidal acid-adjusted polymer with polypropylene”
358/2011	Vestergaard Frandsen SA Switzerland (Priority 06-04-2011 Bangladesh)	“A biocidal polyolefin yarn with 3-12 filaments”

### 19-05-2011

359/2011	Huma Ikram Darakhshan Jabeen Haleem Muhammad Abdul Haleem Department of Biochemistry University of Karachi, Pakistan	“Low but not High Dose of Buspirone could Attenuate Apomorphine-induced Sensitization”
360/2011	Huma Ikram Darakhshan Jabeen Haleem Farhat Batool Erum Shireen Department of Biochemistry University of Karachi, Pakistan	“Buspirone can normalize Apomorphin- induced Addiction”
361/2011	Farhat Batool Darakhshan Jabeen Haleem Huma Ikram Erum Shireen Muhammad Abdul Haleem Department of Biochemistry University of Karachi, Pakistan Department of Biomedical Engineering, Sir Syed University of Engineering & Technology, Karachi Pakistan	“5-ht-1a receptor agonist 8-oh-dpat attenuates extrapyramidal symptoms associated with antipsychotics”

362/2011	<p>Farhat Batool  Darakhshan Jabeen Haleem  Asad Hussain Shah  Syed Dilnawaz Ahmed  Muhammad Abdul Haleem  Department of Biochemistry  University of Karachi, Pakistan  Department of Biomedical  Engineering, Sir Syed University  of Engineering &amp; Technology,  Karachi Pakistan</p>	<p>“Protective effects of aqueous fruit extract from sea buckthorn (<i>hippophae rhamnoides</i> l. Ssp. <i>Turkestanica</i>) on haloperidol induced orofacial dyskinesia and neuronal alterations in the striatum”</p>
363/2011	<p>Erum Shireen  Darakhshan Jabeen Haleem  Farhat Batool  Huma Ikram  Qurratul-Aen Inam  Tahira Perveen  Muhammad Abdul Haleem  Department of Biochemistry  University of Karachi, Pakistan  Department of Biomedical  Engineering, Sir Syed University  of Engineering &amp; Technology,  Karachi Pakistan</p>	<p>“Reversal of haloperidol-induced parkinsonism and tardive dyskinesia by mianserin”</p>
364/2011	<p>Darakhshan Jabeen Haleem  Erum Shireen  Noreen Samad  Huma Ikram  Farhat Batool  Saida Haider  Muhammad Abdul Haleem  Department of Biochemistry  University of Karachi, Pakistan  Department of Biomedical  Engineering, Sir Syed University  of Engineering &amp; Technology,  Karachi Pakistan</p>	<p>Reversal of haloperidol-induced parkinsonism and tardive dyskinesia by buspirone</p>
365/2011	<p>Syngenta Participations AG  Switzerland  (Priority 21-05-2010 Europe)</p>	<p>“Novel compounds”</p>
366/2011	<p>Bayer CropScience AG  Germany  (Priority 21-05-2010 Europe)</p>	<p>“Herbicide composition for tolerant or resistant cereal crops”</p>

367/2011 Unilever PLC "A Water Purification Device"  
United Kingdom  
(Priority 31-05-2010 India)

**21-05-2011**

368/2011 Dr. Ishtiaq qadri "Bio product for the use as a therapy  
Mr. Waqas Nasir Chaudhry (antibacterial) for the eradication of  
NCVI, NUST, H-12, Islamabad, Citrobacter freundii"  
Pakistan

369/2011 Regeneron Pharmaceuticals, Inc. "Antibodies to human gdf8"  
USA  
(Priority 26-05-2010 USA)

---

## APPLICATION ACCEPTED

Notice is hereby given that the person interested in opposing the grant of Patents to any of the applications referred to below at any time within four months from the date of this Gazette may give notice at the Patent Office on the prescribed Form P-7 of the Patents Rules 18(1) of 2003.

The six figures number shown in the right hand side are those given to applications on acceptance of the complete specification under which the specification will be printed and subsequent proceeding taken.

The figures shown within square brackets after the title of inventions indicate their classification index at acceptance.

Typed copies of the specification which are to open to public inspection can be supplied by the Patent Office on payment of the prescribed charges which may be ascertained on application to the office.


93/2009 Takeda Pharamceutical  
Company Limited,  
Japan

“Dihydropyrido [4,3-d] pyrimidin-5(6h)-one-o-alkyl oxime ether as inhibitor of hsp90”


CO7D 239/84, A61K 31/519

**141199**

The present invention provides an inhibitor of HSP90 of the formula



wherein X is O; R<sub>1</sub> is -L-R<sub>45</sub>; R<sub>2</sub> is selected from the group consisting of hydrogen and methyl; R<sub>3</sub> is of the formula



and the variables as defined in the specification.

## SEALING FEES DUE

Notice is hereby given that the Patent may now be sealed on the application referred to below if it is desired that Patent should be sealed a request on the prescribed Form-10 accompanied by the fee of Rs.2250/- should be sent to the Controller of Patents and Designs, The Patent Office, Karachi.

<b>Accepted No.</b>	<b>Applicant Name</b>	<b>Application No.</b>
140848	F. Hoffmann-LA Roche AG, Switzerland.	404/1995
140849	Abbott Laboratories, USA.	1106/1998
140850	Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.	562/2002
140851	Wyeth USA.	1098/2002
140852	Bayer CropScience AG., Germany.	571/2004
140853	AstraZeneca, United Kingdom.	673/2004
140854	H. Lundbeck A/S, Denmark.	41/2005
140855	Unilever PLC, United Kingdom.	767/2005
140856	Akzo Nobel N.V., Netherland.	1076/2005
140857	Clariant International Ltd., Switzerland.	634/2006
140858	Telenor ASA Norway.	694/2006
140859	Wyeth USA.	896/2006
140860	Honda Motor Co. Limited, Japan.	1168/2006
140861	Polyethylene Technologies Ltd., G.B.	250/2007
140862	Polyethylene Technologies Ltd., G.B.	252/2007
140863	LES Laboratoires Servier, France	373/2007
140864	F. Hoffmann-LA Roche AG, Switzerland.	494/2008
140865	Atlas Elektronik GmbH, Germany.	976/2008
140866	Unilever PLC, United Kingdom.	309/2009

140867	Kindraco Hardware Sendirian Berhad, Malaysia.	939/2009
140868	Tetra Laval Holdings & France SA, Switzerland.	965/2009
140869	Merck Patent GmbH, Germany	1163/2009
140870	Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.	184/2010
140871	AstraZeneca UK Limited, United Kingdom.	547/2010

---

**NEW APPLICATIONS FOR THE INDUSTRIAL DESIGNS**

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Inventor</b>
<b><u>16-05-2011</u></b>			
1	15741	Inhaler (Class- )	Pharmachemie Holdings B.V
2	15742	Inhaler (Class- )	Pharmachemie Holdings B.V

**REGISTRATION OF DESIGNS**

The following designs have been registered.

<b>S. No.</b>	<b>Design No.</b>	<b>Title &amp; Class</b>	<b>Inventor</b>
<b><u>18-05-2011</u></b>			
1	15360	Football (Class-06)	Kicker Sports
2	15361	Football (Class-06)	Kicker Sports
3	15362	Football (Class-06)	Kicker Sports
4	15363	Football (Class-06)	Kicker Sports
5	15364	Football (Class-06)	Kicker Sports
6	15365	Football (Class-06)	Kicker Sports
7	15366	Football (Class-06)	Kicker Sports
8	15367	Football (Class-06)	Kicker Sports
9	15368	Goalkeeper's Gloves (Class-06)	Kicker Sports

**(SABIR GUL)**  
Controller of Patents  
& Registrar of Designs  
**Ph: 99215056**